Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa

Abatacept

药品：阿巴西普

Patterns of change in patient assessments of physical function with scores of the Health Assessment Questionnaire (HAQ) among users of SC Abatacept for RA since the commencement of a CUP in South Africa's private sector

Demographic characteristics (age, gender, education and population group) of patients

Clinical characteristics (comorbidities including Tuberculosis, medication use, and adverse events) of patients

Reasons for discontinuation based on the reasons mentioned in Questionnaire

Reasons for discontinuation: defined as common responses given for stopping treatment and include death, adverse event, lack of efficacy, lost to follow-up, withdrawal of consent, or other reasons

Reasons for skipping treatment based on the reasons mentioned in Questionnaire

Reasons for skipping treatment: defined as explanations given for inability to adhere to the recommended treatment regime and include fear of side effects, lack of access (too far) to medicine, inconvenient to use, too busy or forgetting, or other reasons

Association of demographic and clinical characteristics based on Standard Disability Index of the Health Assessment Questionnaire (HAQ-DI) scores

Changes in physical functioning against clinical trial and long-term extension phase data based incidence of adverse events

Adverse events: defined as any untoward medical event in a patient whether related or unrelated to SC abatacept and may include any sign (laboratory finding), symptom, or disease